Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02217475 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis
A Phase 2 study of Nonalcoholic Steatohepatitis, sponsored by Tobira Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 289
- Enrollment target
- 20
- Study locations
NCT02217475: Completed Phase 2 study of Nonalcoholic Steatohepatitis, sponsored by Tobira Therapeutics.
NCT02217475 is a Phase 2 study of Nonalcoholic Steatohepatitis that has completed, run by Tobira Therapeutics. The registered enrollment target is 289 participants, below the 693-participant average among 30 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02217475, a Phase 2 study of Nonalcoholic Steatohepatitis, has completed, sponsored by Tobira Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 289 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether cenicriviroc is effective and safe in the treatment of nonalcoholic steatohepatitis (NASH) in adult participants with liver fibrosis.
Primary Outcome
Hepatic histological improvement in Nonalcoholic Fatty Liver Disease Activity Score (NAS) at Year 1 was defined as a decrease (improvement) in NAS by ≥ 2 with at least a 1-point reduction in either lobular inflammation or hepatocellular ballooning and with no concurrent worsening of fibrosis stage. The NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8 with the higher score indicating
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cenicriviroc
Study Locations (20)
California
- - Rialto
- - San Diego
- - San Diego
- - San Francisco
Maryland
- - Baltimore
- - Baltimore
- - Chevy Chase
- - Lutherville
Arizona
- - Phoenix
- - Tucson
Florida
- - Miami
- - Tampa
Massachusetts
- - Boston
- - Worcester
Alabama
- - Dothan
Colorado
- - Littleton
Illinois
- - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2014-09-18 |
| Est. Completion | 2017-06-22 |
| Phase | Phase 2 |
What the finished NCT02217475 record still lists
NCT02217475 is an interventional study that assigns participants to a tested intervention. The registered 289 participants enrollment target is mid-sized for trials with a published cap, below the 693-participant average among 30 other Nonalcoholic Steatohepatitis trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02217475 names 20 study sites across 11 states, led by California, Maryland, Arizona.
Frequently Asked Questions
What is clinical trial NCT02217475 about?
NCT02217475 is a clinical study titled "Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis". The purpose of this study is to determine whether cenicriviroc is effective and safe in the treatment of nonalcoholic steatohepatitis (NASH) in adult participants with liver fibrosis.
What is the current status of trial NCT02217475?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 289 participants. The study started on 2014-09-18. Estimated completion is 2017-06-22.
What conditions does trial NCT02217475 study?
This clinical trial studies the following conditions: Nonalcoholic Steatohepatitis.
What interventions are being tested in trial NCT02217475?
The interventions under investigation include: Placebo (DRUG), Cenicriviroc (DRUG).
Who is sponsoring clinical trial NCT02217475?
This trial is sponsored by Tobira Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02217475 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02217475's enrollment target sits among peer trials
289 7th of 30 higher than 24 of 30 other Nonalcoholic Steatohepatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nonalcoholic Steatohepatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
RECRUITING · Phase 2
-
Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
RECRUITING · Phase 2
-
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
ACTIVE NOT RECRUITING · Phase 2
-
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06465199 · 289 participants · Phase 1
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI